A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides  and Sézary syndrome.

A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. Br J Dermatol. 2019 Sep 12;: Authors: Papps T, McCormack C, Buelens O, Van der Weyden C, Twigger R, Campbell BA, Dickinson M, Prince HM Abstract Two histone deacetylase inhibitors (HDACi), vorinostat and romidepsin have been approved by regulatory agencies in parts of the world for the treatment of relapsed/refractory Mycosis Fungoides (MF) and Sézary Syndrome (SS) based on positive Phase II trial results.1,2 Panobinostat has activity in MF/SS, and is approved in the United States for the treatment of myeloma.3 HDACi are of different classes, with vorinostat and panobinostat both hydroxamic acids with pan-HDAC inhibitor activity, and romidepsin a cyclic peptide with specificity to Class I HDAC. PMID: 31512229 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research